Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idio… Read more
Market Cap & Net Worth: Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Contineum Therapeutics, Inc. Class A Common Stock (NASDAQ:CTNM) has a market capitalization of $402.35 Million ($402.35 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13298 globally and #5546 in its home market, demonstrating a -2.40% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Contineum Therapeutics, Inc. Class A Common Stock's stock price $13.22 by its total outstanding shares 30446111 (30.45 Million).
Contineum Therapeutics, Inc. Class A Common Stock Market Cap History: 2024 to 2026
Contineum Therapeutics, Inc. Class A Common Stock's market capitalization history from 2024 to 2026. Data shows change from $447.10 Million to $372.05 Million (-9.34% CAGR).
Index Memberships
Contineum Therapeutics, Inc. Class A Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #361 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1300 of 3165 |
Weight: Contineum Therapeutics, Inc. Class A Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Contineum Therapeutics, Inc. Class A Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Contineum Therapeutics, Inc. Class A Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CTNM by Market Capitalization
Companies near Contineum Therapeutics, Inc. Class A Common Stock in the global market cap rankings as of March 19, 2026.
Key companies related to Contineum Therapeutics, Inc. Class A Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Contineum Therapeutics, Inc. Class A Common Stock Historical Marketcap From 2024 to 2026
Between 2024 and today, Contineum Therapeutics, Inc. Class A Common Stock's market cap moved from $447.10 Million to $ 372.05 Million, with a yearly change of -9.34%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $372.05 Million | +6.91% |
| 2025 | $348.00 Million | -22.17% |
| 2024 | $447.10 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Contineum Therapeutics, Inc. Class A Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $402.35 Million USD |
| MoneyControl | $402.35 Million USD |
| MarketWatch | $402.35 Million USD |
| marketcap.company | $402.35 Million USD |
| Reuters | $402.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.